Loading data for IRON — first visit, this takes a few seconds.

Alerte

Disc Medicine Inc. (IRON)

NasdaqGM: IRON · Prix en temps réel · USD

80.05

+1.21 (1.53%)

À la clôture : Aug 18, 2026, 8:00 PM

1.53% (1D)

Aucune donnée disponible

Cours acheteur	56.05
Capitalisation boursière	3.08B
Chiffre d’affaires (ttm)	n/a
Résultat net (ttm)	-245.89M
Bêta	2.06
EPS (ttm)	-6.59
Ratio P/E (ttm)	n/a
P/E prévisionnel	-11.05
P/B (ttm)	4.77
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

Cours vendeur	77.67
Volume	377,081
Volume moy. (20D)	527,925
Ouverture	78.53
Clôture précédente	78.84
Fourchette du jour	74.46 - 80.09
Intervalle de 52 semaines	40.00 - 99.50
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de IRON

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood c...

[En savoir plus]

Industrie Biotechnology

Secteur Healthcare

Date d’introduction Aug 12, 2020

Employés 165

Bourse NasdaqGM

Symbole boursier IRON

Site web https://www.discmedicine.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Disc Medicine s’élevait à 0, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à -212.18M, soit une hausse de 94.03%.

États financiers

Surprise sur les résultats

Disc Medicine a publié ses résultats trimestriels le Jul 30, 2026 :

Chiffre d’affaires de $0 est inférieur aux estimations de $0, avec NaN% croissance en glissement annuel.

EPS de -1.54 dépasse les estimations de 0.23, avec 2.53% croissance en glissement annuel.

Prochaine publication des résultats

Disc Medicine Inc. devrait publier ses résultats le Nov 5, 2026, avant l’ouverture du marché.
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure

Actualités

2 mois il y a · Simply Wall St.

How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients

Disc Medicine has launched a U.S. expanded access program for its investigational drug bitopertin, allowing eligible erythropoietic protoporphyria and X-linked protoporphyria patients aged 12 and abov...

2 mois il y a · MarketBeat

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enro...

3 mois il y a · Simply Wall St.

A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter

Disc Medicine (IRON) stock has been in focus after law firms began investigating potential securities claims linked to allegedly misleading business information following an FDA Complete Response Lett...

3 mois il y a · Motley Fool

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.

5 mois il y a · Simply Wall St.

Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals

Event Overview and Immediate Context Disc Medicine (IRON) has drawn fresh attention after recent share price moves, with the stock up about 3% over the past day but showing a negative return over the ...

Page 1 de 2

Disc Medicine Inc. (IRON)